Darlene Horton sails into Nile as CMO
This article was originally published in Scrip
Nile Therapeutics, a biopharmaceutical company that develops novel therapeutics for heart failure patients, has appointed Dr Darlene Horton chief medical officer. Dr Horton was previously CMO of Itero Biopharmaceuticals, and before that, senior vice-president of clinical research at Scios, a Johnson & Johnson company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.